2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 271-273
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, CLL, B Cell Lymphoma, Research, Fundamental Science, Translational Research
PAPER

369 Targeting LEF1-dependent BCL2 repression to overcome venetoclax resistance in lymphoid malignancies

Kadriye Nehir Cosgun, PhD, Stephen Martindale, BA2, Jing Wang, PhD3, Mark E Robinson, PhD4, Anna Mathew Lawrence5, Takeshi Ito, MD-PhD6, Tianhao Yin7, Jodi Forward, MD8, Matthew S Davids, MD, MMSc9, Markus Müschen, MD-PhD10
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
3 Department of Medical Oncology, Boston, Massachusetts, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
8 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Pediatrics, Section of Hematology-Oncology, New Haven, Connecticut, United States
9 Department of Medical Oncology, Boston, Massachusetts, United States
10 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States

Background: Lymphoid malignancies, including B-ALL, T-ALL and CLL express high levels of the transcription factor LEF1 that forms a complex with β-catenin to drive canonical WNT signaling. However, despite high LEF1 expression in B- and T-ALL and CLL, we recently showed that these lymphoid malignancies express 50- to 130-fold lower levels of β-catenin than solid tumors. Instead, lymphoid cells evolved and critically depend on lymphoid-specific high-efficiency β-catenin protein degradation - creating a targetable vulnerability in lymphoid malignancies. For instance, clinical GSK3B-inhibitors interfere with this mechanism and induce β-catenin accumulation and selective toxicity at low nanomolar concentrations; however, the molecular basis of this lineage-specific vulnerability remains incompletely understood.

Results: To comprehensively identify mechanism of B-cell specific sensitivity to GSK3B inhibition, we performed genome-wide chemogenomic CRISPR screens in NALM6 B-ALL cells treated with subtherapeutic doses (IC20) of three GSK3B inhibitors that demonstrated favorable safety profiles in clinical trials (CHIR99021, AZD1080, and LY2090314). Across all three compounds, LEF1 and β-catenin emerged as the strongest genetic rescue hits. Computational analyses of gene expression biomarkers for responses to the GSK3B-inhibitor CHIR99021 (CTD2 screen) demonstrated that LEF1 expression strongly correlated with sensitivity to GSK3B inhibition across 131 lymphoid malignancies. Genetic deletion of β-catenin or LEF1 in B-ALL and T-ALL PDX models completely rescued GSK3B inhibitor-induced cytotoxicity. Proteomic analyses in in B-ALL, T-ALL and CLL samples identified LEF1 as a major β-catenin interaction partner together with the lymphoid-specific transcriptional repressors IKZF1 and IKZF3 and, multiple components of the NuRD repressor complex (GATAD2A/B, CHD4, MTA2). LEF1 deletion impaired nuclear localization of β-catenin, disrupted assembly of the β-catenin-NuRD complexes and reversed the transcriptional program induced by GSK3B inhibition.

Integrated transcriptomic and epigenomic analyses demonstrated that LEF1 and β-catenin interactions broadly activated canonical Wnt signaling while selectively repressing a subset of lymphoid-specific enhancers co-occupied by IKZF1. The most profoundly repressed regulatory elements included the BCL2 superenhancer, resulting in marked suppression of BCL2 expression. LEF1 deletion restored BCL2-enhancer activity and reversed transcriptional repression, establishing LEF1 as the critical mediator linking β-catenin accumulation to BCL2 repression.

Because GSK3B inhibition substantially reduced BCL2 expression, we hypothesized that lymphoid malignancies become increasingly dependent on residual BCL2 activity for survival. Across multiple B-ALL, T-ALL and CLL Richter syndrome PDX models, LY2090314 combined with venetoclax produced robust synergistic cytotoxicity, with Zero Interaction Potency (ZIP) synergy scores exceeding either agent alone, with highest ZIP scores between 36 and 51. Consistent with unusually high synergy between GSK3B- and BCL2-inhibitors, dynamic BH3 profiling revealed that GSK3B-inhibitors induced dose-dependent apoptotic priming and restored venetoclax-sensitivity in venetoclax-resistant PDX models. Notably, low nanomolar concentrations of LY2090314 restored venetoclax sensitivity in venetoclax-resistant (VR) mantle cell lymphoma cell lines eliciting ZIP scores between 55 and 63. These results highlight GSK3B inhibition as a clinically actionable approach to resensitize patients with venetoclax-refractory B- and T-cell malignancies.

Conclusions: GSK3B inhibition creates a previously unrecognized therapeutic vulnerability in lymphoid malignancies through LEF1-dependent transcriptional repression of the BCL2 super-enhancer. This adaptive transcriptional rewiring increases reliance on residual BCL2 activity, providing a mechanistic basis for potent synergy with venetoclax. Given the established clinical use of venetoclax and the favorable safety and PK/PD  profiles of multiple GSK3B inhibitors in clinical trials, these findings provide a strong rationale for GSK3B inhibitor-venetoclax combinations in relapsed/refractory B-cell malignancies. Furthermore, LEF1 expression and BCL2 dependence may serve as predictive biomarkers to identify patients most likely to benefit from this mechanism-based therapeutic strategy.

Kadriye Nehir Cosgun, PhD: No relevant conflicts of interest to declare.